Document Detail


The addition of pioglitazone in type 2 diabetics poorly controlled on insulin therapy: a meta-analysis.
MedLine Citation:
PMID:  20816593     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: To quantify the effect of a pioglitazone on glycemic control and lipid parameters, as well as the risk of adverse events when incorporated into the treatment regimen of patients with type 2 diabetes inadequately controlled on insulin.
METHODS: The electronic databases PubMed, Embase and The Cochrane Library were searched systematically to identify randomized controlled trials (RCTs) of pioglitazone therapy in patients with type 2 diabetes mellitus (DM) inadequately controlled after treatment with insulin. Data on change of haemoglobin A1C (HbA1c), fasting plasma glucose (FPG), lipid parameters and risk of hypoglycemic, edema events were extracted from each study and pooled according to fixed effect model or random effect model in meta-analyses.
RESULTS: Four RCTs including 1767 patients were included. The pooled estimate of change in HbA1c from baseline was 1.22% (95% CI 1.01-1.44, p<0.001 vs. baseline) and of change in FPG from baseline was 1.63 mmol/l (95% CI 0.75-2.50, p<0.001 vs. baseline). Pioglitazone significantly increased high-density lipoprotein cholesterol (HDL-c) level (0.2 mmol/L, 95%CI: 0.13-0.28) and low-density lipoprotein cholesterol (LDL-c) level (0.10 mol/L, 95%CI: 0.09-0.17), and lowered triglyceride (TG) level (0.05 mmol/L, 95%CI: 0.01-0.09). The odds of experiencing a hypoglycemic event in pioglitazone-treated arms was significantly higher than comparator treatments (RR=1.57, 95% CI 1.12-2.20, p<0.001). The case was the same with edema (RR=2.42, 95% CI 1.67-3.50, p<0.001).
CONCLUSIONS: Our study implied that in patients with type 2 DM whose control is inadequate on insulin therapy, the additional pioglitazone could significantly improve glucose metabolism and might have a positive effect on important components of the lipid profile, which may have important implications in reducing the risk of cardiovascular disease, a major long-term complication in type 2 diabetes mellitus. Besides, the adverse events (AEs) were well tolerated.
Authors:
Aihua Tan; Yunfei Cao; Ning Xia; Zengnan Mo; Feng Gao
Related Documents :
19279303 - Obstructive sleep apnea among obese patients with type 2 diabetes.
8973883 - Impaired vibration perception threshold and long-term mean hba1c in patients with type ...
1790693 - Diagnosis and classification of diabetes mellitus.
Publication Detail:
Type:  Journal Article; Meta-Analysis    
Journal Detail:
Title:  European journal of internal medicine     Volume:  21     ISSN:  1879-0828     ISO Abbreviation:  Eur. J. Intern. Med.     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-09-06     Completed Date:  2010-12-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9003220     Medline TA:  Eur J Intern Med     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  398-403     Citation Subset:  IM    
Copyright Information:
Copyright (c) 2010. Published by Elsevier B.V.
Affiliation:
Guangxi Medical University, Nanning, Guangxi, PR China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cardiovascular Diseases / epidemiology
Diabetes Mellitus, Type 2 / drug therapy*,  epidemiology
Drug Therapy, Combination
Humans
Hypoglycemic Agents / administration & dosage*,  adverse effects
Insulin / administration & dosage*,  adverse effects
Risk Factors
Thiazolidinediones / administration & dosage*,  adverse effects
Chemical
Reg. No./Substance:
0/Hypoglycemic Agents; 0/Thiazolidinediones; 11061-68-0/Insulin; 111025-46-8/pioglitazone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Percutaneous treatment for symptomatic pancreatic pseudocysts: Long-term results in a single center.
Next Document:  Impact of exercise intensity and duration on insulin sensitivity in women with T2D.